Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
1206852-99-5
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:hasMolecularFormula |
C26H28F3N5O4S
|
| gptkbp:hasSMILES |
CC1=CC(=C(C=C1N2C=NC(=NC2N3CCOCC3)N4CCOCC4)N5CCN(CC5)S(=O)(=O)C)C(=O)OC(F)(F)F
|
| gptkbp:hasUNII |
6Q1K1V0A1T
|
| https://www.w3.org/2000/01/rdf-schema#label |
taselisib
|
| gptkbp:investigatedBy |
gptkb:cancer
|
| gptkbp:isPI3KInhibitor |
true
|
| gptkbp:IUPACName |
gptkb:5-[4,6-Dimorpholin-4-yl-1,3,5-triazin-2-yl]-2-methyl-4-(4-methylsulfonylpiperazin-1-yl)phenyl_2,2,2-trifluoroacetate
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
46216347 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:GDC-0032
|
| gptkbp:target |
gptkb:PI3K_beta
gptkb:PI3K_gamma gptkb:PI3K_delta gptkb:PI3K_alpha |
| gptkbp:bfsParent |
gptkb:PIK3CA
|
| gptkbp:bfsLayer |
5
|